Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics (TNGX)
NASDAQ:TNGX
Holding TNGX?
Track your performance easily
TNGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.15 - $13.03
Previous Close$8.3
Volume2.65M
Average Volume (3M)907.37K
Market Cap
$889.30M
Enterprise Value$605.03M
Total Cash (Recent Filing)$322.11M
Total Debt (Recent Filing)$37.84M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Nov 06, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding107,144,465
10 Day Avg. Volume1,918,931
30 Day Avg. Volume907,367
Standard Deviation0.29
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.59
Price to Sales (P/S)20.92
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.23
Enterprise Value/Gross Profit16.56
Enterprise Value/Ebitda-4.99
Forecast
1Y Price Target
$15.83Price Target Upside90.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Tango Therapeutics News
PremiumStock Analysis & Ideas
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Cash And FundingTango ended 2Q24 with $322.1M in cash, cash equivalents, and marketable securities, which should provide an operational runway into 2027.
Financial PerformanceTango reported its 2Q24 financial results, recording a net loss of $0.24 per share—substantively narrower than the previously estimated net loss of $0.36 per share—mainly due to higher-than-projected quarterly revenue.
Market OpportunityThe market is undervaluing Tango at $10 per share, with an estimated market opportunity of over 200,000 patients and over $10 billion total addressable market in the U.S. and EU for MTAP-deleted cancers.
Bears Say
Clinical ResultsNegative clinical results with the lead asset, TNG908, could hurt investor confidence.
Market CompetitivenessCompetitor agent IDE397 delivers solid initial results in MTAP-deleted urothelial and lung cancer.
Pipeline AdvancementsDelays in advancing pipeline candidates into registrational programs may hinder future growth prospects.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TNGX FAQ
What was Tango Therapeutics’s price range in the past 12 months?
Tango Therapeutics lowest stock price was $5.15 and its highest was $13.03 in the past 12 months.
What is Tango Therapeutics’s market cap?
Currently, no data Available
When is Tango Therapeutics’s upcoming earnings report date?
Tango Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 3 days.
How were Tango Therapeutics’s earnings last quarter?
Tango Therapeutics released its earnings results on Aug 07, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.345 by $0.105.
Is Tango Therapeutics overvalued?
According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued.
Does Tango Therapeutics pay dividends?
Tango Therapeutics does not currently pay dividends.
What is Tango Therapeutics’s EPS estimate?
Tango Therapeutics’s EPS estimate is -$0.37.
How many shares outstanding does Tango Therapeutics have?
Tango Therapeutics has 107,144,460 shares outstanding.
What happened to Tango Therapeutics’s price movement after its last earnings report?
Tango Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.345. Following the earnings report the stock price went down -3.219%.
Which hedge fund is a major shareholder of Tango Therapeutics?
Among the largest hedge funds holding Tango Therapeutics’s share is Deerfield Management Company, LP. It holds Tango Therapeutics’s shares valued at 13M.
---
Tango Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.83 (90.72% Upside)
$15.83 (90.72% Upside)
Blogger Sentiment
Neutral
TNGX Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 378.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.37%
12-Months-Change
Fundamentals
Return on Equity
-50.58%
Trailing 12-Months
Asset Growth
0.56%
Trailing 12-Months
Company Description
Tango Therapeutics
BCTG Acquisition Corp is a blank check company.
---
TNGX Stock 12 Month Forecast
Average Price Target
$15.83
▲(90.72% Upside)
Technical Analysis
Precision BioSciences
―
Fate Therapeutics
―
Rocket Pharmaceuticals
―
Editas Medicine
―
Best Analysts Covering TNGX
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+21.35%
reiterated a buy rating 3 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +21.35% per trade.
---